Helping pharma create the world’s most impactful medicines.

Through a combination of research and acquisitions, we have created a partnered portfolio with a variety of underlying technologies. We focus on infrastructure-light platforms that are scalable, have broad applicability and will enable us to generate higher royalties for our company and shareholders. This diversification provides the added benefits of exposure to a wider variety of science, more licensing opportunities and lower impact of individual patent expiry.

Our platform technologies available for out-license include Captisol®, a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.

Roughly 40% of small molecule drug candidates have low solubility, which is why the world’s top pharmaceutical companies partner with Ligand and use Captisol as an important tool in the drug development process. Our Captisol partners include Amgen, Merck, Pfizer, Takeda and Gilead, which used it to improve solubility for Remdesivir for the treatment of COVID-19.

Interested in partnering with us?

Our platform technologies available for out-license include Captisol®, a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.

Roughly 40% of small molecule drug candidates have low solubility, which is why the world’s top pharmaceutical companies partner with Ligand and use Captisol as an important tool in the drug development process. Our Captisol partners include Amgen, Merck, Pfizer, Takeda and Gilead, which used it to improve solubility for Remdesivir for the treatment of COVID-19.

Interested in partnering with us?